Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ines Figueiredo

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
European Urology Oncology|March 12, 2026
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate CancerRafael Grochot, Christina Guo, Suzanne Carreira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Cell Reports|January 19, 2018
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate CancerXiangyi Li, GuemHee Baek, Susmita G Ramanand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid TumorsTimothy A Yap, Brent O'Carrigan, Marina S Penney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
Characterizing CDK12-Mutated Prostate CancersPasquale Rescigno, Bora Gurel, Rita Pereira, et al.
European Urology Oncology|May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate CancerMaría Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Adam Sharp, Wei Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
European Urology Oncology|March 12, 2026
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate CancerRafael Grochot, Christina Guo, Suzanne Carreira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Cell Reports|January 19, 2018
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate CancerXiangyi Li, GuemHee Baek, Susmita G Ramanand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid TumorsTimothy A Yap, Brent O'Carrigan, Marina S Penney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
Characterizing CDK12-Mutated Prostate CancersPasquale Rescigno, Bora Gurel, Rita Pereira, et al.
European Urology Oncology|May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate CancerMaría Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Adam Sharp, Wei Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Pageof 8